RX.V
Price:
$10.7
Market Cap:
$126.17M
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatm...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1996-05-08
Stock Exchange
TSXV
Ticker
RX.V
According to BioSyent Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 17.83. This represents a change of 17.64% compared to the average of 15.16 of the last 4 quarters.
The mean historical PE Ratio of BioSyent Inc. over the last ten years is 24.77. The current 17.83 PE Ratio has changed 7.10% with respect to the historical average. Over the past ten years (40 quarters), RX.V's PE Ratio was at its highest in in the December 2014 quarter at 55.33. The PE Ratio was at its lowest in in the March 2020 quarter at 8.36.
Average
24.77
Median
23.15
Minimum
15.78
Maximum
52.17
Discovering the peaks and valleys of BioSyent Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 74.74%
Maximum Annual PE Ratio = 52.17
Minimum Annual Increase = -50.56%
Minimum Annual PE Ratio = 15.78
Year | PE Ratio | Change |
---|---|---|
2023 | 16.56 | 4.93% |
2022 | 15.78 | -5.44% |
2021 | 16.69 | -38.40% |
2020 | 27.09 | 39.14% |
2019 | 19.47 | -5.03% |
2018 | 20.50 | -23.92% |
2017 | 26.95 | 1.04% |
2016 | 26.67 | 3.40% |
2015 | 25.79 | -50.56% |
2014 | 52.17 | 74.74% |
The current PE Ratio of BioSyent Inc. (RX.V) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
16.34
5-year avg
19.12
10-year avg
24.77
BioSyent Inc.’s PE Ratio is greater than Cipher Pharmaceuticals Inc. (11.83), greater than Covalon Technologies Ltd. (-94.97), less than Viemed Healthcare, Inc. (33.86), greater than Hamilton Thorne Ltd. (-431.84), greater than Knight Therapeutics Inc. (-29.26),
Company | PE Ratio | Market cap |
---|---|---|
11.83 | $384.60M | |
-94.97 | $79.15M | |
33.86 | $402.21M | |
-431.84 | $212.88M | |
-29.26 | $619.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioSyent Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioSyent Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BioSyent Inc.'s PE Ratio?
How is the PE Ratio calculated for BioSyent Inc. (RX.V)?
What is the highest PE Ratio for BioSyent Inc. (RX.V)?
What is the 3-year average PE Ratio for BioSyent Inc. (RX.V)?
What is the 5-year average PE Ratio for BioSyent Inc. (RX.V)?
How does the current PE Ratio for BioSyent Inc. (RX.V) compare to its historical average?